OneDayMD.com

Information related to the COVID-19 pandemic has been overwhelming and confusing as well. Information is all over the place and various groups are giving conflicting statements. How do you make sense from all these fragmented information? As of December 2021, there are more than 1,000 studies that have been published on treatments for COVID-19. You can review the details of these trials on  c19early.com . New ones are being added every day. The aim of this article is to organise and summarise the best available evidence in one place.          McCullough et al. Reviews in Cardiovascular Medicine, 2020 Most doctors know the need to focus now on early treatment as the most immediate and practical way to reduce hospitalizations and death. This is your guide to help you know your options, and to use with your personal physician. Most reviews analyze the drug from a mono-therapy perspective and tend to draw conclusion on whether that one drug is effective or not for COVID-19. However, we do

Many of us don’t follow the best diets. As a result, our bodies may be lacking in certain essential vitamins and minerals. The good news is that, overall, most Americans are getting enough of some important nutrients—like folate, vitamin D, and iodine—according to the   CDC . The bad news? Many of us aren’t getting enough of   all   the major vitamins and minerals our bodies need. For instance, according to the most recent   US Dietary Guidelines , a number of Americans aren’t getting sufficient amounts of dietary fiber, potassium, choline, magnesium, calcium, iron, and vitamins, A, D, E, and C. So, what do we do when we have one or more nutritional deficiencies? We either tweak our food choices or take supplements to fill these gaps. In fact, 86% of Americans take vitamins or supplements, according to a   poll   conducted on behalf of the American Osteopathic Association. But, if you have more than one nutritional deficiency—or are already taking

SYDNEY, Oct 14, 2021 - (ACN Newswire) - Topelia Australia, a biotech company established to commercialise a novel ATT treatment for Australians in quarantine, has launched an investment program designed to keep the invention Australian owned - while rolling out treatment to the world. - Topelia announces US$25 mil Series A capital raise to fund manufacture and clinical trials of the COVID-19 Antiviral Triple Therapy (ATT). - Topelia has secured exclusive global patent rights to COVID-19 Antiviral Triple Therapy from Prof Thomas Borody. - Borody's track record includes effective treatment for Peptic Ulcers & Crohn's Disease, recolonisation of bowel microbiome, and 3 FDA approved drugs on the market. - Based on current research, the ATT provides an inexpensive and medically efficacious treatment for the prevention and early treatment of COVID-19. The company is raising USD$25 million from investors in Australia, Asia and USA. The company said: "Topelia proposes to offer

A   Sydney   gastroenterologist who has been enthusiastically promoting an unapproved Covid-19 treatment, including to Australian politicians and general practitioners, has filed a patent in the US for the same treatment, allowing him to commercialise and profit from it, if approved. Prof Thomas Borody has been quoted  in medical newsletters  and  publications , and in news outlets including the  Financial Review , the  Daily Telegraph  and  the Australian , promoting what he describes as a “triple therapy protocol” to treat and cure Covid-19. The protocol involves a combination of the anti-parasitic drug ivermectin, zinc and the antibiotic doxycycline. In December 2020 Borody filed a patent in the US for therapeutic combinations of drugs, including a combination of ivermectin, an antibiotic and zinc. Patenting a treatment means the owner of the patent is allowed to exclusively manufacture, market and profit from the drug until the patent expires, usually after 20 years. Borody did not

The World Health Organization on November 26, 2021 classified the B.1.1.529 variant, or Omicron, as a SARS-CoV-2 "variant of concern," saying it may spread more quickly than other forms of coronavirus. The Delta variant remains dominant worldwide, accounting for 99.9% of U.S. cases, and it is not yet clear whether Omicron will be able to displace Delta, said Dr. Graham Snyder, medical director, infection prevention and hospital epidemiology at University of Pittsburgh Medical Center. But the new variant has over 30 mutations in the part of the virus that current vaccines target. It is also suspected of driving a spike in new infections in South Africa.  COVID-19 Omicron Variant Symptoms South Africa’s National Institute for Communicable Diseases (NICD) has said that “currently no unusual symptoms have been reported following infection with the B.1.1.529 variant.” NICD also said that as with other infectio